Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
BACKGROUND: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS: A comparison of interventional therap...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/ https://www.ncbi.nlm.nih.gov/pubmed/21455104 http://dx.doi.org/10.12659/MSM.881714 |
_version_ | 1782255103822004224 |
---|---|
author | Wiggermann, Philipp Sieron, Dominik Brosche, Christiane Brauer, Thomas Scheer, Fabian Platzek, Ivan Wawrzynek, Wojciech Stroszczynski, Christian |
author_facet | Wiggermann, Philipp Sieron, Dominik Brosche, Christiane Brauer, Thomas Scheer, Fabian Platzek, Ivan Wawrzynek, Wojciech Stroszczynski, Christian |
author_sort | Wiggermann, Philipp |
collection | PubMed |
description | BACKGROUND: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading. RESULTS: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651±76 days vs. 414±43 days for cTACE (p=0.01). CONCLUSIONS: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol. |
format | Online Article Text |
id | pubmed-3539521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-35395212013-04-24 Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) Wiggermann, Philipp Sieron, Dominik Brosche, Christiane Brauer, Thomas Scheer, Fabian Platzek, Ivan Wawrzynek, Wojciech Stroszczynski, Christian Med Sci Monit Clinical Research BACKGROUND: This study is an outcome evaluation of the Drug-Eluting-Bead-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplation and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis. MATERIAL/METHODS: A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading. RESULTS: The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651±76 days vs. 414±43 days for cTACE (p=0.01). CONCLUSIONS: Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol. International Scientific Literature, Inc. 2011-04-01 /pmc/articles/PMC3539521/ /pubmed/21455104 http://dx.doi.org/10.12659/MSM.881714 Text en © Med Sci Monit, 2011 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. |
spellingShingle | Clinical Research Wiggermann, Philipp Sieron, Dominik Brosche, Christiane Brauer, Thomas Scheer, Fabian Platzek, Ivan Wawrzynek, Wojciech Stroszczynski, Christian Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) |
title | Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) |
title_full | Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) |
title_fullStr | Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) |
title_full_unstemmed | Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) |
title_short | Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) |
title_sort | transarterial chemoembolization of child-a hepatocellular carcinoma: drug-eluting bead tace (deb tace) vs. tace with cisplatin/lipiodol (ctace) |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539521/ https://www.ncbi.nlm.nih.gov/pubmed/21455104 http://dx.doi.org/10.12659/MSM.881714 |
work_keys_str_mv | AT wiggermannphilipp transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT sierondominik transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT broschechristiane transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT brauerthomas transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT scheerfabian transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT platzekivan transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT wawrzynekwojciech transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace AT stroszczynskichristian transarterialchemoembolizationofchildahepatocellularcarcinomadrugelutingbeadtacedebtacevstacewithcisplatinlipiodolctace |